What Is Tibial Disease? Causes, Symptoms, and Treatment

Tibial disease is a form of peripheral artery disease in which the arteries below the knee become narrowed or blocked, starving the foot and lower leg of blood flow. The term covers atherosclerosis, calcification, or both in the anterior tibial, posterior tibial, and peroneal arteries. Because these vessels are smaller and harder to treat than the arteries higher up in the leg, tibial disease carries an outsized risk of tissue loss and amputation, especially for people with diabetes or kidney disease.

The Arteries Involved

Just below the knee, the popliteal artery splits into three branches that supply the lower leg and foot. The anterior tibial artery crosses from behind the leg to the front and runs down along the outer side of the shin. The remaining trunk then divides again: the posterior tibial artery descends along the inner calf, while the peroneal artery tracks deeper between muscles on the back of the leg.¹ All three arteries are roughly pencil-lead thin, and their small caliber is part of what makes tibial disease so troublesome: it takes relatively little plaque or calcium to choke off blood flow in a vessel this narrow.

The posterior tibial artery is particularly important clinically because the pulse you or your doctor can feel behind the inner ankle bone comes from this vessel. When that pulse disappears or weakens, tibial disease is high on the list of possible causes.

Who Gets Tibial Disease and Why

Peripheral artery disease in general can strike the arteries at any level of the leg, but the pattern of where plaque builds up varies depending on a person’s risk factors. In people without diabetes, atherosclerosis tends to concentrate in the larger arteries above the knee, particularly the iliac and femoral segments. Diabetes flips that pattern. A meta-analysis pooling data from multiple studies found that people with diabetes were roughly twice as likely to have disease in the tibial arteries compared with those without diabetes, and significantly less likely to have disease in the upper-leg segments.² This preference for small, below-the-knee vessels is one of the reasons diabetic foot problems so frequently end in amputation: the blockages sit in precisely the arteries that feed the foot.

Chronic kidney disease is the other major driver. As kidney function declines, phosphate and calcium levels become harder to regulate, and the smooth-muscle cells lining the tibial arteries begin to behave more like bone-forming cells. Researchers who isolated cells from the posterior tibial arteries of patients with severe kidney disease found that these cells calcified at dramatically higher rates than normal arterial cells when exposed to high-phosphate conditions.³ The result is stiff, calcium-encrusted arteries that cannot expand or contract properly. This kind of calcification, called medial arterial calcification or Mönckeberg sclerosis, differs from ordinary plaque buildup. Instead of fatty deposits narrowing the channel, the artery wall itself turns rigid, which can coexist with or accelerate the plaque-based narrowing.

The standard risk factors for any form of peripheral artery disease also apply: smoking, high blood pressure, high cholesterol, and age. But diabetes and kidney disease deserve special emphasis because they preferentially target the tibial vessels and make treatment harder once the disease is established.

How the Arteries Change

Two processes can damage tibial arteries, and they often overlap. The first, atherosclerosis, involves fatty deposits forming inside the artery’s inner lining, gradually narrowing the channel through which blood flows. The second, medial calcification, is a distinct process that happens in the muscular middle layer of the artery wall. Studies of calcified tibial vessels have shown that smooth-muscle cells in these arteries start producing bone-related proteins like alkaline phosphatase and bone sialoprotein while shutting down protective proteins that normally prevent mineral deposits.⁴ This is not passive calcium settling into aging tissue; the cells are actively remodeling themselves to produce bone where it does not belong.

The practical consequence is an artery that is both narrowed by plaque and encased in a stiff calcium shell. A heavily calcified tibial artery resists the balloons and stents used during endovascular procedures, makes surgical bypass more difficult because there is less soft tissue to sew into, and falsely elevates the ankle blood-pressure readings used in standard screening tests.

Symptoms and Warning Signs

Tibial disease progresses through a spectrum of severity. In its earliest stage, you may have no symptoms at all, particularly if collateral vessels (small detour pathways) compensate for the reduced flow. As the disease worsens, the classic symptom is claudication: cramping or aching in the calf that starts during walking and resolves within a few minutes of rest. The pain occurs because the muscles demand more oxygen than the diseased arteries can deliver during exercise.

When blockages become severe enough, blood flow fails to meet the leg’s needs even at rest. This stage is called critical limb ischemia, defined by the presence of rest pain, non-healing ulcers, or gangrene caused by peripheral arterial blockages persisting for more than two weeks.⁵ Rest pain typically hits the forefoot and toes, often worsening at night when the legs are elevated and gravity no longer helps push blood downhill. Patients commonly describe hanging their foot over the side of the bed or sleeping in a recliner for relief.

Non-healing wounds are another hallmark. A small cut, blister, or pressure sore on the foot that refuses to close after weeks of care should raise suspicion for underlying tibial disease, especially in someone with diabetes. The wound persists because the surrounding tissue simply is not getting enough blood to fuel the repair process.⁶ In the most advanced cases, tissue begins to die, turning black at the tips of the toes or along the edges of the foot. At this point, the condition is limb-threatening, and intervention is urgent.

How Tibial Disease Is Diagnosed

The first-line screening tool for peripheral artery disease in general is the ankle-brachial index, a simple comparison of blood pressure measured at the ankle and the arm. A low ratio points to arterial blockages in the leg. The catch with tibial disease, especially in patients with diabetes or kidney disease, is that calcified arteries do not compress normally under the blood-pressure cuff. The reading comes back falsely normal or even abnormally high, masking the disease underneath. In these cases, the toe-brachial index is more reliable, since the tiny arteries in the toes tend to resist calcification better than the ankle-level tibial vessels.⁷

Once tibial disease is suspected, imaging maps the exact location and severity of the blockages. Duplex ultrasound, which combines standard ultrasound with Doppler blood-flow measurements, is non-invasive and widely available. It performs well in the thigh and upper leg, but accuracy drops below the knee, where the vessels are smaller and harder to visualize. CT angiography provides a detailed roadmap of the arteries but can also lose accuracy in the tibial segments; one study comparing it against the gold standard of catheter-based angiography found only moderate agreement for below-the-knee vessels.⁸ When CT results are inconclusive, or when metal hardware from prior surgery creates image artifacts, digital subtraction angiography via catheter remains the definitive test.⁹

Medical Management

Regardless of whether a procedure is planned, medical therapy forms the foundation of treatment. The core pillars include blood-pressure control, cholesterol management with statins, blood-sugar optimization in diabetics, and smoking cessation for current smokers.¹⁰ These measures address the systemic disease process that caused the tibial blockages in the first place, and without them, any procedure performed on the arteries is fighting an uphill battle against ongoing damage.

Antiplatelet therapy is standard to reduce the risk of heart attack, stroke, and worsening leg symptoms. Low-dose aspirin has been the traditional choice, but clopidogrel has shown somewhat better results with similar bleeding risk. More recently, evidence from randomized trials has shown that combining low-dose rivaroxaban with aspirin provides additional protection against both cardiovascular events and limb-related complications in people with symptomatic peripheral artery disease.¹⁰

Supervised exercise therapy is another evidence-based treatment that often gets overlooked. Structured walking programs progressively build tolerance to claudication pain and encourage the body to develop collateral blood-flow pathways around the blockages. For patients who cannot walk on a treadmill because of wounds, joint problems, or balance issues, alternatives like upper-body ergometry or recumbent stepping can still produce meaningful improvements in walking distance and functional capacity.¹¹

Endovascular Treatment

When medical management alone is not enough to prevent tissue loss or control rest pain, restoring blood flow directly becomes the priority. Endovascular procedures, performed through a catheter threaded into the arteries, are the less-invasive option. The basic technique is balloon angioplasty: a tiny balloon is inflated inside the narrowed tibial artery to push the plaque aside and widen the channel. The problem is that tibial arteries have high rates of re-narrowing after plain balloon angioplasty, sometimes within months.

Drug-coated balloons aim to solve this by delivering a thin layer of anti-proliferative medication to the artery wall during inflation, discouraging scar tissue from regrowing. A meta-analysis of trials comparing drug-coated balloons with plain balloons for below-the-knee disease found that drug-coated balloons cut the rate of re-narrowing roughly in half and reduced the need for repeat procedures, without increasing the risk of death or amputation.¹² Another analysis found that the benefit in reducing repeat interventions was strongest at one year, with the advantage fading over longer follow-up periods.¹³ Drug-coated balloons have been better established in the larger arteries above the knee, where one trial showed primary patency rates above 80% at one year compared with roughly half that for plain balloons.¹⁴ Below the knee, results are more modest, but the direction of benefit is consistent.

Surgical Bypass

In surgical bypass, a vein harvested from the patient’s own leg (usually the great saphenous vein) is grafted from a healthy artery above the blockage to a target artery below it, creating a new route for blood to reach the foot. For tibial disease, the bypass typically connects the femoral or popliteal artery to one of the tibial vessels or a foot artery.

The landmark BEST-CLI trial, published in the New England Journal of Medicine, compared bypass surgery with endovascular therapy in patients with chronic limb-threatening ischemia. Among patients who had a good-quality vein available for grafting, surgery produced significantly better outcomes: a composite of major adverse limb events and death occurred in about 43% of surgical patients versus 57% of endovascular patients over a median follow-up of nearly three years.¹⁵ When no good-quality vein was available and an alternative conduit had to be used, the advantage of surgery narrowed and was no longer statistically significant. The takeaway: bypass remains a powerful option, but it depends heavily on having a suitable vein to work with.

Looking specifically at peroneal artery interventions, one comparative study found that bypass achieved primary patency around 48% at one year versus about 23% for endovascular treatment, though there was no significant difference in amputation rates between the two approaches.¹⁶ These numbers highlight a reality of tibial disease treatment: even the best available interventions have fairly modest durability, and repeat procedures are common regardless of which approach is chosen.

The Angiosome Concept in Revascularization

The foot is divided into regions, each fed by a specific artery, a concept borrowed from plastic surgery called the angiosome model. When a wound sits in the territory of the posterior tibial artery, for example, the idea is that opening or bypassing that specific artery (direct revascularization) should heal the wound faster than restoring flow through one of the other tibial arteries whose territory does not overlap the wound. A meta-analysis of studies comparing direct and indirect revascularization found that directing blood flow to the wound’s own angiosome was associated with significantly faster wound healing.¹⁷ The angiosome approach is not always feasible, however, because the target artery may be too calcified or too diseased to treat. In practice, vascular specialists aim for direct revascularization when they can and accept indirect flow when they must.

Wound Care and Limb Preservation Programs

Restoring blood flow is only half the equation when tibial disease has already caused tissue damage. Healing a diabetic foot wound typically requires a coordinated effort: offloading pressure from the wound, managing infection, optimizing nutrition, and ensuring adequate perfusion. Specialized wound-care clinics categorize lower-extremity wounds by their underlying cause and tailor treatment accordingly: neuropathic wounds need pressure redistribution and biomechanical correction, ischemic wounds need vascular intervention, and the common neuro-ischemic wound needs both.¹⁸

Regions that have implemented formal multidisciplinary limb-preservation programs, bringing together vascular surgeons, podiatrists, wound-care nurses, endocrinologists, and physical therapists under one coordinated system, have seen significantly lower hospitalization rates and shorter hospital stays for diabetes-related foot complications compared with regions relying on standard-of-care approaches.¹⁹ Access to these programs varies widely, but the evidence consistently favors team-based care over any single specialist acting alone.

When No Target Artery Remains

Some patients with tibial disease reach a point where all three tibial arteries and the foot arteries are too diseased or completely blocked, leaving no viable target for a bypass graft or balloon procedure. These so-called “no-option” patients have historically faced near-certain amputation. A newer technique called percutaneous deep vein arterialization reroutes arterial blood into the foot’s venous system, essentially running blood backward through the veins to supply the starved tissue.²⁰ Early feasibility studies of the LimFlow system, the device furthest along in development, have shown encouraging rates of limb salvage at one year in patients who otherwise had no revascularization option available.²¹ The approach remains investigational, and larger trials are needed, but for a population that previously had no good options, it represents a genuine shift in what is possible.

Prognosis and What Drives Outcomes

Tibial disease carries worse raw outcomes than peripheral artery disease confined to the upper leg. A study comparing patients with isolated tibial disease to those with more proximal blockages found lower three-year survival rates, lower amputation-free survival, and lower limb salvage in the tibial group. However, when researchers controlled for the conditions that tend to travel with tibial disease, particularly tissue loss and end-stage kidney disease, tibial disease by itself was not an independent predictor of poor outcomes.²² In other words, the worse prognosis largely reflects the sicker patient population that develops tibial disease rather than something inherently untreatable about the tibial arteries themselves. This is actually somewhat reassuring: it means that aggressively managing diabetes, kidney disease, and wounds can move the needle on outcomes even when the arterial anatomy is unfavorable.

Disparities in Amputation Risk

Not everyone with tibial disease faces the same chance of losing a limb, and the gaps are disturbingly wide. Among people with both diabetes and peripheral artery disease, amputation risk varies significantly by geography, race, and income. Rural residents, Black patients, Native American patients, and those with low socioeconomic status carry the highest risk of amputation.²³ These differences persist even after accounting for disease severity and are driven in part by unequal access to vascular specialists, limb-preservation programs, and the kind of coordinated care described above. A patient in a rural community with limited vascular surgery coverage faces a fundamentally different trajectory than one near a major medical center, even with the same degree of arterial disease. Addressing tibial disease as a public-health problem means grappling with these access gaps alongside the biology.